FRX Related Analyst EPS View
-
Forest Laboratories (FRX) 'Day of Reckoning' Not Far Off
-
Needham & Company Maintians a 'Hold' on Forest Laboratories (FRX); Q1 Review; Reviewing FDA Calendar
-
Baird Maintains a 'Neutral' on Forest Laboratories (FRX); Q1 a Net-Neutral Event
-
Barclays Adjusts Estimates on Forest Laboratories (FRX); Q1 Preview: Icahn Not Issue Til August
-
Barclays Previews Forest Laboratories (FRX) Analyst Day Meeting: Shares Becoming Popular Destination to 'Hide'
-
Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
-
Cantor Fitzgerald Maintains a 'Buy' on Forest Laboratories (FRX); Raising PT and Estimates
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Continued Growth Challenges, But There Is A Success Factor
Back to FRX Stock Lookup
